Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

British Journal of Cancer advance online publication, October 3 2017. doi:10.1038/bjc.2017.308

Authors: Eiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Kohei Shitara, Hideaki Bando, Sachiyo Mimaki, Chikako Nakai, Koutatsu Matsushima, Yutaka Suzuki, Kiwamu Akagi, Takeharu Yamanaka, Shogo Nomura, Satoshi Fujii, Hiroyasu Esumi, Masaya Sugiyama, Nao Nishida, Masashi Mizokami, Yasuhiro Koh, Yukiko Abe, Atsushi Ohtsu & Katsuya Tsuchihara

http://ift.tt/2xYlq9W